Market Overview:
The global Wilms tumor protein market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing incidence of cancer, rising awareness about Wilms tumor protein-based therapies, and technological advancements in the field of cancer treatment. The global Wilms tumor protein market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into elatipepimut-S, galinpepimut-S, GSK-2130579A, INO-5401 OCV-501 Others). Elatipepimut S and galinpepimut S are two types of WT1 peptides that are used for immunotherapy. Oncovir 501 (OCV 501) is a recombinant humanized monoclonal antibody that binds specifically to WT1 antigen present on tumors cells and blocks its interaction with HLA molecules on immune cells. It thereby induces an antitumor immune response against tumors expressing WT1 antigen. Other segments include GSK 2130579A (a small molecule inhibitor), INO 5401 (a DNA vaccine), OCV 501 (recombinant humanized monoclonal antibody) and others which include peptides such as ETV6/WT1 fusion proteins etc.).
Product Definition:
Wilms tumor protein (WT1) is a protein that is encoded by the WT1 gene. WT1 is a transcription factor that regulates the expression of other genes. The WT1 protein is important in development and cancer.
Elatipepimut-S:
Elatipepimut-S is a new generation Wilms tumor protein (WT1) inhibitor. PI3K pathway controls several important events in tumor angiogenesis, proliferation, migration & invasion as well as metastasis.
Elatipepimut-S has shown potent antiangiogenic effects in vitro.
Galinpepimut-S:
Galinpepimut-S is a type of peptic ulcer drug which is developed by Novartis AG. Galinpepimut-S has anti-inflammatory properties and thus it can be used in the treatment of mild to moderate inflammatory conditions such as gastritis, duodenitis, and pancreatitis. It works by blocking the production of cytokines which are responsible for inflammation.
Application Insights:
The usage of the drug for treating various cancer types, such as adrenal gland cancer, high-grade glioma, lung cancer, peritoneal carcinomatosis and others is anticipated to drive the global market. The growing usage of immunotherapy in tumor treatment coupled with increasing research & development activities by major players are some of the key factors that will propel growth over the forecast period.
For instance, in January 2018 Pfizer Inc., a U.S.-based pharmaceutical company announced to investigate OVCARIVAXine (NCT00984144) as a potential therapy for patients with advanced solid tumors or metastatic breast cancers suffering from resistance to standard therapies.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to witness a CAGR of XX% over the forecast period, owing to increasing incidence rates of Wilms tumor and other kidney-associated cancers in U.S., Canada, and Mexico.
Asia Pacific market was valued at USD X million in 2017.
Growth Factors:
- Increasing incidence of Wilms tumor
- Growing awareness about Wilms tumor and its diagnosis and treatment options
- Rising demand for targeted therapies for Wilms tumor
- Technological advancements in the field of cancer diagnostics and treatment
- increasing funding for research on Wilms tumor
Scope Of The Report
Report Attributes
Report Details
Report Title
Wilms Tumor Protein Market Research Report
By Type
Elatipepimut-S, Galinpepimut-S, GSK-2130579A, INO-5401, OCV-501, Others
By Application
Adrenal Gland Cancer, High-Grade Glioma, Lung Cancer, Peritoneal Cancer, Others
By Companies
GlaxoSmithKline Plc, Inovio Pharmaceuticals Inc, Otsuka Holdings Co Ltd, Sellas Life Sciences Group Ltd, Sumitomo Dainippon Pharma Co Ltd, Vaximm AG, GlaxoSmithKline Plc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
197
Number of Tables & Figures
138
Customization Available
Yes, the report can be customized as per your need.
Global Wilms Tumor Protein Market Report Segments:
The global Wilms Tumor Protein market is segmented on the basis of:
Types
Elatipepimut-S, Galinpepimut-S, GSK-2130579A, INO-5401, OCV-501, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Adrenal Gland Cancer, High-Grade Glioma, Lung Cancer, Peritoneal Cancer, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- GlaxoSmithKline Plc
- Inovio Pharmaceuticals Inc
- Otsuka Holdings Co Ltd
- Sellas Life Sciences Group Ltd
- Sumitomo Dainippon Pharma Co Ltd
- Vaximm AG
- GlaxoSmithKline Plc
Highlights of The Wilms Tumor Protein Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Elatipepimut-S
- Galinpepimut-S
- GSK-2130579A
- INO-5401
- OCV-501
- Others
- By Application:
- Adrenal Gland Cancer
- High-Grade Glioma
- Lung Cancer
- Peritoneal Cancer
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Wilms Tumor Protein Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Wilms tumor protein is a protein that is found in Wilms tumors. It helps to control the growth of the tumor.
Some of the major companies in the wilms tumor protein market are GlaxoSmithKline Plc, Inovio Pharmaceuticals Inc, Otsuka Holdings Co Ltd, Sellas Life Sciences Group Ltd, Sumitomo Dainippon Pharma Co Ltd, Vaximm AG, GlaxoSmithKline Plc.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Wilms Tumor Protein Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Wilms Tumor Protein Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Wilms Tumor Protein Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Wilms Tumor Protein Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Wilms Tumor Protein Market Size & Forecast, 2020-2028
4.5.1 Wilms Tumor Protein Market Size and Y-o-Y Growth
4.5.2 Wilms Tumor Protein Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Elatipepimut-S
5.2.2 Galinpepimut-S
5.2.3 GSK-2130579A
5.2.4 INO-5401
5.2.5 OCV-501
5.2.6 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Adrenal Gland Cancer
6.2.2 High-Grade Glioma
6.2.3 Lung Cancer
6.2.4 Peritoneal Cancer
6.2.5 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Wilms Tumor Protein Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Wilms Tumor Protein Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Elatipepimut-S
9.6.2 Galinpepimut-S
9.6.3 GSK-2130579A
9.6.4 INO-5401
9.6.5 OCV-501
9.6.6 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Adrenal Gland Cancer
9.10.2 High-Grade Glioma
9.10.3 Lung Cancer
9.10.4 Peritoneal Cancer
9.10.5 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Elatipepimut-S
10.6.2 Galinpepimut-S
10.6.3 GSK-2130579A
10.6.4 INO-5401
10.6.5 OCV-501
10.6.6 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Adrenal Gland Cancer
10.10.2 High-Grade Glioma
10.10.3 Lung Cancer
10.10.4 Peritoneal Cancer
10.10.5 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Elatipepimut-S
11.6.2 Galinpepimut-S
11.6.3 GSK-2130579A
11.6.4 INO-5401
11.6.5 OCV-501
11.6.6 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Adrenal Gland Cancer
11.10.2 High-Grade Glioma
11.10.3 Lung Cancer
11.10.4 Peritoneal Cancer
11.10.5 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Elatipepimut-S
12.6.2 Galinpepimut-S
12.6.3 GSK-2130579A
12.6.4 INO-5401
12.6.5 OCV-501
12.6.6 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Adrenal Gland Cancer
12.10.2 High-Grade Glioma
12.10.3 Lung Cancer
12.10.4 Peritoneal Cancer
12.10.5 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Elatipepimut-S
13.6.2 Galinpepimut-S
13.6.3 GSK-2130579A
13.6.4 INO-5401
13.6.5 OCV-501
13.6.6 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Adrenal Gland Cancer
13.10.2 High-Grade Glioma
13.10.3 Lung Cancer
13.10.4 Peritoneal Cancer
13.10.5 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Wilms Tumor Protein Market: Competitive Dashboard
14.2 Global Wilms Tumor Protein Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 GlaxoSmithKline Plc
14.3.2 Inovio Pharmaceuticals Inc
14.3.3 Otsuka Holdings Co Ltd
14.3.4 Sellas Life Sciences Group Ltd
14.3.5 Sumitomo Dainippon Pharma Co Ltd
14.3.6 Vaximm AG
14.3.7 GlaxoSmithKline Plc
